To Evaluate the Safety and the Pharmacokinetics of NVP-2203
NCT ID: NCT05725252
Last Updated: 2024-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
50 participants
INTERVENTIONAL
2023-05-28
2023-07-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate the PK, PD, Safety and Drug Tolerance of JW0302 in Healthy Volunteers
NCT05784155
Safety, Tolerability, and Pharmacokinetics of DD-S052P in Healthy Volunteers
NCT07347223
To Evaluate the PK, PD, Safety and Drug Tolerance in Healthy Volunteers
NCT05433844
Clinical Trial to Evaluate the Safety and Pharmacokinetics of YHP1903 in Healthy Volunteers
NCT04225052
Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers
NCT06070857
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NVP-2203
After fasting (except water) for at least 10 hours before dosing, oral administration of investigational product once daily on Period 1(or Period 2)
NVP-2203
NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2)
NVP-2203-R
After fasting (except water) for at least 10 hours before dosing, oral administration of investigational product once daily on Period 1(or Period 2)
NVP-2203-R
administration of active comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NVP-2203
NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2)
NVP-2203-R
administration of active comparator
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI of \>18.0 kg/m2 and \<30.0 kg/m2 subject, weight more than 50kg(45 kg or more for woman)
Exclusion Criteria
* Inadequate subject for the clinical trial by the investigator's decision
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NVP Healthcare
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jaewoo Kim
Role: PRINCIPAL_INVESTIGATOR
H Plus Yangji Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
H Plus Yangji Hospital
Seoul, Nambusunhwan-ro, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NVP-2203_BA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.